Compare Corning Incorporated (GLW) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Johnson & Johnson — how do they compare? Corning Incorporated trades at $156.5 (market cap $131.65B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 4.7× Corning Incorporated's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Johnson & Johnson for 129 Days on average.
| GLW | JNJ | |
|---|---|---|
Market Cap | $131.65B | $618.09B |
Volume | 8,992,522 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $255.79 | $278.43 |
52-Week Low | $78.03 | $186.00 |
Typical Hold Time | 36 Days | 129 Days |
Enterprise Value | $138.52B | $646.37B |
Dividend Yield | 0.73% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $156.69, down 3.99% amid a bearish technical signal, though fundamentals show strong recovery with 2025 revenue reaching $15.63B and net income surging to $1.60B. The company recently secured a multi-year $3B fiber supply deal with AT&T, boosting its optical communications segment. Analyst consensus remains positive with a $171.25 price target and 57% buy ratings, but technical indicators show selling pressure with support at $149.
GLW presents a mixed outlook: the AT&T deal and earnings beat streak support growth, but high valuation ratios (P/E 70.43) and bearish technicals pose near-term risks. Investors should weigh strong cash flow projections ($1.0B net CF in 2026) against patent litigation concerns and elevated debt levels. The stock offers upside to analyst targets if execution continues.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
